24/7 Market News- Seelos Therapeutics Signs MTA with U.S. Army Medical Materiel Development Activity for Potential PTSD treatment

September 24, 2024

DENVER, Colo., Sep 24, 2024 (247marketnews.com)- Seelos Therapeutics (Nasdaq: SEEL) reported that it signed a Material Transfer Agreement (MTA) with the U.S. Army Medical Materiel Development Activity (USAMMDA) to evaluate SLS-002’s (intranasal racemic ketamine) potential for treatment of post-traumatic stress disorder (PTSD) for the U.S. Department of Defense’s (DOD) Military and Veterans Adaptive Platform Clinical Trial (“M-PACT”).

The SLS-002 cohort is the only ketamine-based therapy selected for inclusion in this study, which is expected to commence this year.

Raj Mehra, Ph.D., Chief Executive Officer of Seelos, commented, “Approximately 13 million people in the U.S. live with PTSD and there have been no new drugs approved in the last two decades for people suffering the effects of PTSD.

“I believe that the inclusion of SLS-002 in this study is due to the robust amount of anecdotal evidence that ketamine has the potential to be an effective therapeutic for the symptoms of PTSD and other related conditions. Our data to date with SLS-002 suggest that its intranasal formulation could provide a rapid onset of benefit while mitigating the side effects seen through the other routes of administration of ketamine. We are proud to be included in this study and look forward to commencing the dosing of SLS-002.”

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (SEEL)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.